Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.55 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 10/20 | 0.48 |
| ▸ | HTR1A | P08908 | 9/20 | 0.48 |
| ▸ | DRD2 | P14416 | 5/20 | 0.48 |
| ▸ | HTR6 | P50406 | 5/20 | 0.48 |
| ▸ | HRH2 | P25021 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | WNT3 | P56703 | 1/20 | 0.47 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13873237 | 0.93 | EPHX2 (0.56) | EPHX2UCHL1HTR7HTR1ADRD2 | |
| SCHEMBL14413609 | 0.82 | UCHL1 (0.56) | EPHX2UCHL1HTR7HTR1ADRD2 | |
| SCHEMBL13890207 | 0.79 | EPHX2 (0.59) | EPHX2UCHL1HTR7HTR1ADRD2 | |
| SCHEMBL6538880 | 0.79 | MEN1 (0.66) | EPHX2UCHL1HTR7HTR1ADRD2 | |
| SCHEMBL4602370 | 0.78 | MMP13 (0.63) | HTR7HTR1ASFRP1 | |
| SCHEMBL13873155 | 0.77 | RORC (0.43) | EPHX2WNT3SFRP1RORCKMT2A | |
| SCHEMBL14413047 | 0.76 | EPHX2 (0.55) | EPHX2UCHL1HTR7HTR1ADRD2 | |
| SCHEMBL13873146 | 0.76 | EPHX2 (0.56) | EPHX2UCHL1HTR7HTR1ADRD2 | |
| Hydrochloric Acid SCHEMBL4881432 | 0.75 | DPP4 (0.49) | EPHX2HTR7HTR1ARORC | |
| Hydrochloric Acid SCHEMBL4881423 | 0.75 | DPP4 (0.49) | EPHX2HTR7HTR1ARORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885UCHL1 93/4885HTR7 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.